AdipoGen, Inc. is a newly formed biotech
company whose foundation is immunological knowledge and
technology.
Its mother company was KOMED that had
an expertise in both microbiology and immunology.
A great emphasis is currently placed
on the selected life science areas,
which meet the demands of the
post genome era; production of quality monoclonal antibodies,
development of the immunological diagnostic kits for metabolic
diseases, and discovery of the genes causing obesity or type
II diabetes using proteomics and molecular biological technologies.
This disease-centered investigation
with an in depth infrastructure of the modern biological science
may enable the company to be further transformed into a finest
pharmaceutical company in the future.
